ECSP22030119A - DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION - Google Patents
DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPIONInfo
- Publication number
- ECSP22030119A ECSP22030119A ECSENADI202230119A ECDI202230119A ECSP22030119A EC SP22030119 A ECSP22030119 A EC SP22030119A EC SENADI202230119 A ECSENADI202230119 A EC SENADI202230119A EC DI202230119 A ECDI202230119 A EC DI202230119A EC SP22030119 A ECSP22030119 A EC SP22030119A
- Authority
- EC
- Ecuador
- Prior art keywords
- dosage forms
- bupropion
- enantiomerically enriched
- methods
- pure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Esta divulgación se refiere a las formas de dosificación que contienen un bupropión enantioméricamente enriquecido o puro, tal como un exceso enantiomérico del (S)-bupropión, del (S)-bupropión enantioméricamente enriquecido o del (S)-bupropión enantioméricamente puro, y a los métodos de uso de estas formas de dosificación. Estas formas de dosificación se pueden administrar a los seres humanos en una cantidad reducida en comparación con la cantidad de bupropión racémico que se administraría en la misma situación.This disclosure relates to dosage forms containing enantiomerically enriched or pure bupropion, such as an enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion, and to methods of using these dosage forms. These dosage forms can be administered to humans in a reduced amount compared to the amount of racemic bupropion that would be administered in the same situation.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/052210 WO2020061486A2 (en) | 2018-09-20 | 2019-09-20 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US202062971174P | 2020-02-06 | 2020-02-06 | |
| US202062978626P | 2020-02-19 | 2020-02-19 | |
| US202062992060P | 2020-03-19 | 2020-03-19 | |
| US16/830,637 US20200222339A1 (en) | 2018-09-20 | 2020-03-26 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US16/907,691 US11433035B2 (en) | 2018-09-20 | 2020-06-22 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22030119A true ECSP22030119A (en) | 2022-05-31 |
Family
ID=74884634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202230119A ECSP22030119A (en) | 2019-09-20 | 2022-04-13 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP4031121A4 (en) |
| JP (2) | JP2022549192A (en) |
| KR (1) | KR20220066930A (en) |
| CN (1) | CN114423417A (en) |
| AU (2) | AU2020349419B2 (en) |
| BR (1) | BR112022005045A2 (en) |
| CA (1) | CA3154718A1 (en) |
| CO (1) | CO2022003126A2 (en) |
| CR (1) | CR20220119A (en) |
| EC (1) | ECSP22030119A (en) |
| IL (1) | IL291514A (en) |
| MX (1) | MX2022003346A (en) |
| PE (1) | PE20221314A1 (en) |
| WO (1) | WO2021055124A1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1051166A1 (en) * | 1998-01-29 | 2000-11-15 | Sepracor, Inc. | Pharmaceutical uses of optically pure (+) -bupropion |
| US6150420A (en) * | 1998-06-01 | 2000-11-21 | Theramax, Inc. | Method for enhanced brain delivery of bupropion |
| US20190216800A1 (en) * | 2013-11-05 | 2019-07-18 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| MX2013014166A (en) * | 2013-12-03 | 2015-06-10 | Inst De Investigacion En Quimica Aplic S A De C V | Active enantiomers and the salts thereof for treating obesity. |
| US9732031B2 (en) * | 2013-12-20 | 2017-08-15 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
| MX2020008704A (en) * | 2018-02-23 | 2020-12-07 | Axsome Therapeutics Inc | Dosage forms and methods for enantiomerically enriched or pure bupropion. |
-
2020
- 2020-08-18 MX MX2022003346A patent/MX2022003346A/en unknown
- 2020-08-18 WO PCT/US2020/046755 patent/WO2021055124A1/en unknown
- 2020-08-18 BR BR112022005045A patent/BR112022005045A2/en unknown
- 2020-08-18 AU AU2020349419A patent/AU2020349419B2/en active Active
- 2020-08-18 PE PE2022000441A patent/PE20221314A1/en unknown
- 2020-08-18 KR KR1020227013095A patent/KR20220066930A/en active Search and Examination
- 2020-08-18 JP JP2022517743A patent/JP2022549192A/en active Pending
- 2020-08-18 CN CN202080065520.4A patent/CN114423417A/en active Pending
- 2020-08-18 CR CR20220119A patent/CR20220119A/en unknown
- 2020-08-18 EP EP20866164.5A patent/EP4031121A4/en active Pending
- 2020-08-18 CA CA3154718A patent/CA3154718A1/en active Pending
-
2022
- 2022-03-18 CO CONC2022/0003126A patent/CO2022003126A2/en unknown
- 2022-03-20 IL IL291514A patent/IL291514A/en unknown
- 2022-04-13 EC ECSENADI202230119A patent/ECSP22030119A/en unknown
-
2024
- 2024-01-05 AU AU2024200081A patent/AU2024200081A1/en active Pending
- 2024-02-22 JP JP2024025971A patent/JP2024059812A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024059812A (en) | 2024-05-01 |
| KR20220066930A (en) | 2022-05-24 |
| EP4031121A1 (en) | 2022-07-27 |
| CO2022003126A2 (en) | 2022-04-19 |
| CR20220119A (en) | 2022-06-22 |
| AU2020349419B2 (en) | 2023-11-02 |
| CN114423417A (en) | 2022-04-29 |
| BR112022005045A2 (en) | 2022-07-05 |
| IL291514A (en) | 2022-05-01 |
| MX2022003346A (en) | 2022-04-11 |
| AU2024200081A1 (en) | 2024-01-25 |
| PE20221314A1 (en) | 2022-09-07 |
| EP4031121A4 (en) | 2022-11-30 |
| CA3154718A1 (en) | 2021-03-25 |
| AU2020349419A1 (en) | 2022-03-24 |
| JP2022549192A (en) | 2022-11-24 |
| WO2021055124A1 (en) | 2021-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2018005612A (en) | AGENTS, USES AND METHODS FOR THE TREATMENT OF SINUCLEINOPATIA | |
| DOP2019000040A (en) | SUBSTITUTED PIRROLIZINE COMPOUNDS AND USES OF THE SAME | |
| MX2020000734A (en) | S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same. | |
| CL2019001293A1 (en) | Agents, uses and methods for the treatment of synucleinopathy. | |
| CO2019009258A2 (en) | Fast and controlled administration of compositions with restored entourage effects | |
| WO2020061486A3 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| CL2019000248A1 (en) | Modulators of the nmda spiro-lactam receptor and use thereof | |
| CL2019002218A1 (en) | Triple combination formulations and methods to treat or reduce the risk of cardiovascular disease. | |
| CL2019000247A1 (en) | Modulators of the nmda spiro-lactam receptor and use thereof. | |
| CR20180228A (en) | ATTACHED THERAPY WITH 25-HYDROXY VITAMIN D AND ARTICLES THEREOF | |
| CL2019000249A1 (en) | Modulators of the nmda spiro-lactam and bis-spiro-lactam receptor and use thereof. | |
| CL2020002166A1 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion. | |
| CL2019002574A1 (en) | Modulators of pcsk9 expression. | |
| AR105894A1 (en) | COMPOSITION FOR TOPICAL APPLICATION THAT INCLUDES ISOSORBID DIMETHYL, A POLYOL, AND A PHENOLIC OR POLYPHENOLIC ANTIOXIDANT | |
| MX2018006005A (en) | Formulations comprising oxalate salts of teneligliptin and solvates thereof. | |
| DOP2018000211A (en) | COMPOSITIONS AND METHODS TO STABILIZE ALFAVIRUS WITH IMPROVED FORMULATIONS | |
| ECSP22030119A (en) | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | |
| UY37261A (en) | COMBINED FORMULATION OF THREE ANTIVIRAL COMPOUNDS | |
| CO2020008769A2 (en) | Modulators of the dnm2 expression | |
| BR112021011755A8 (en) | METHOD TO PROVIDE AN ORAL TREATMENT BENEFIT WITH THE USE OF A LOW SOLUBILITY CALCIUM AND FLUORIDE COMPOUND | |
| CO2020009271A2 (en) | Compounds that can be used as a tumor inhibitor, method of their preparation and their application | |
| NI202000095A (en) | METHODS FOR MODULATING PLASMA LEVELS OF TETRABENAZINE METABOLITES USING BUPROPION | |
| CO2016001336A1 (en) | Method and composition and kit to treat erectile dysfunction | |
| CR20190329A (en) | MODULATORS OF COMPLEMENT FACTOR Bi |